Scroll Down
Dorsata and Aspira–leaders in AI-powered care in Women’s Health–have partnered to launch an electronic health record-integrated module for Aspira’s OvaSuiteSM tests. The module is designed to streamline clinical documentation and facilitate evidence-based decision support for the management and treatment of adnexal masses. Our module pairs the functionality and ease of Dorsata’s EHR overlay with Aspira’s innovative clinical solutions to provide a simple yet powerful tool to guide and facilitate the clinical management of adnexal masses.
For women with an indeterminate/benign or newly discovered adnexal mass, the OvaWatch test provides a non-surgical, clinical monitoring solution to estimate the risk profile and potentially avoid unnecessary surgeries. For women scheduled for surgery, the Ova1 test provides a risk score, using multiple biomarkers and menopausal status to determine if referrals to a gynecologic oncologist is recommended.
Together, Dorsata and Aspira have created the Adnexal Mass Module, a streamlined clinical decision support tool designed to facilitate surgical decisions, referrals, and monitoring of adnexal masses for our providers utilizing Aspira’s OvaSuite tests. Using Dorsata’s EHR overlay technology, providers can order testing, track imaging and test results, and assess patient risks, all within one convenient module. To learn more about this tool, Dorsata’s EHR overlay and how it can improve care for adnexal mass patients, visit our listing on the Athena Marketplace below.
Let us know a little about your organization and we’ll reach out to schedule a discussion about the challenges you face and how we can help.